<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00979628</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00020328a</org_study_id>
    <nct_id>NCT00979628</nct_id>
  </id_info>
  <brief_title>Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (DM)</brief_title>
  <acronym>Basal Plus</acronym>
  <official_title>Basal Bolus Versus Basal Insulin Regimen for the Treatment of Hospitalized Patients With Type 2 Diabetes Mellitus: a Randomized, Open Labeled, Non-inferiority Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guillermo Umpierrez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas A&amp;M University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood glucose levels in medical and surgery patients with diabetes are associated with
      increased risk of in-hospital complications and death. Improved glucose control with insulin
      injections may improve clinical outcome and prevent some of the hospital complications.
      Numerous studies have shown that high blood glucose increases the risk of wound infection,
      kidney failure and death. It is not known; however, what is the best insulin regimen in
      patients who will undergo surgery. The use of repeated injections of regular insulin is
      commonly used for glucose control in hospitalized patients with diabetes. Recently, the
      combination of Lantus® and Apidra® insulins has been shown to improve glucose control with
      lower rate of hypoglycemia (low blood sugar). The investigators' recent preliminary data also
      indicate that a single daily dose of glargine plus corrective doses of glulisine before meals
      if needed (Basal Plus) is effective in the management of medical and surgical patients with
      type 2 diabetes mellitus (T2DM). The average daily blood glucose (BG) levels in patients
      treated with Basal Plus is equivalent to levels in patients treated with Basal Bolus with
      glargine once daily plus glulisine before meals (basal bolus regimen). The mean daily BG
      levels in patients treated with basal plus are lower than those reported in patients treated
      with sliding scale regular insulin (SSRI). Accordingly, the present study aims to determine
      which insulin treatment is best for glucose control in hospitalized patients with diabetes
      admitted to general medicine wards. Glargine, glulisine, and regular insulins are approved
      for use in the treatment of patients with diabetes by the FDA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 375 subjects with type 2 diabetes will be recruited in this study. The sites for
      this study are Grady Memorial Hospital, Emory University Hospital, the Atlanta VA Medical
      Center, Scott &amp; White Memorial Hospital and Clinic, and Medical University of South Carolina.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Determine Glycemic Control Between Basal Plus(Glargine Once Daily Plus Corrective Doses of Glulisine Before Meals and Bedtime as Needed), Basal Bolus Approach of Glargine Once Daily Plus Glulisine Before Meals and SSRI</measure>
    <time_frame>during hospitalization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine Differences Between Treatments Arms in # of Hypoglycemic Events</measure>
    <time_frame>during hospitalization</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">375</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Basal Plus Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>glargine subcutaneously once daily plus corrective doses of glulisine subcutaneously before meals and bedtime as needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basal Bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>glargine subcutaneously once daily plus glulisine subcutaneously before meals (plus corrective doses of glulisine as needed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sliding scale regular insulin (SSRI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sliding scale regular insulin subcutaneously four-times daily in patients with T2DM admitted to general medicine and surgery wards.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sliding scale regular insulin (SSRI)</intervention_name>
    <description>four-time daily in patients with T2DM admitted to general medicine and surgery wards.</description>
    <arm_group_label>sliding scale regular insulin (SSRI)</arm_group_label>
    <other_name>Novolin R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basal Bolus</intervention_name>
    <description>glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)</description>
    <arm_group_label>Basal Bolus</arm_group_label>
    <other_name>Lantus (insulin glargine)</other_name>
    <other_name>Apidra (insulin glulisine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basal Plus</intervention_name>
    <description>glargine once daily plus corrective doses of glulisine before meals and bedtime as needed</description>
    <arm_group_label>Basal Plus Regimen</arm_group_label>
    <other_name>Lantus (insulin glargine)</other_name>
    <other_name>Apidra (insulin glulisine)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females between the ages of 18 and 75 years admitted to a general medicine or
             surgical services.

          -  A known history of type 2 diabetes mellitus &gt; 3 months, receiving either diet alone,
             oral monotherapy, or with any combination of oral antidiabetic agents (sulfonylureas,
             meglitinides, metformin, thiazolidinediones, DPP-IV inhibitors).

          -  Patients admitted for non-cardiac elective or emergency surgery or trauma.

          -  Subjects must have an admission BG &gt; 140 mg and &lt; 400 mg/dL without laboratory
             evidence of diabetic ketoacidosis (bicarbonate &lt; 18 mEq/L, pH &lt; 7.30, or positive
             serum or urinary ketones).

        Exclusion Criteria:

          -  Subjects with increased blood glucose concentration, but without a known history of
             diabetes (stress hyperglycemia).

          -  Subjects with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state,
             or ketonuria [32].

          -  Patients with acute critical or surgical illness admitted to the ICU or expected to
             require admission to the ICU.

          -  Patients admitted for CABG or patients receiving continuous insulin infusion.

          -  Patients with clinically relevant hepatic disease (diagnosed liver cirrhosis and
             portal hypertension), corticosteroid therapy, or impaired renal function (creatinine ≥
             3.0 mg/dl).

          -  Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study.

          -  Female subjects are pregnant or breast feeding at time of enrollment into the study.

          -  Patients with recognized or suspected endocrine disorders associated with increased
             insulin resistance, acromegaly, or hyperthyroidism.

          -  Female subjects are pregnant or breast feeding at time of enrollment into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory SOM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425-6240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital and Clinic</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Umpierrez GE, Smiley D, Hermayer K, Khan A, Olson DE, Newton C, Jacobs S, Rizzo M, Peng L, Reyes D, Pinzon I, Fereira ME, Hunt V, Gore A, Toyoshima MT, Fonseca VA. Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. Diabetes Care. 2013 Aug;36(8):2169-74. doi: 10.2337/dc12-1988. Epub 2013 Feb 22.</citation>
    <PMID>23435159</PMID>
  </results_reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2009</study_first_submitted>
  <study_first_submitted_qc>September 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2009</study_first_posted>
  <results_first_submitted>March 24, 2014</results_first_submitted>
  <results_first_submitted_qc>March 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 24, 2014</results_first_posted>
  <last_update_submitted>March 24, 2014</last_update_submitted>
  <last_update_submitted_qc>March 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Inpatient Hyperglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Basal Bolus</title>
          <description>glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)
Basal Bolus : glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)</description>
        </group>
        <group group_id="P2">
          <title>Basal Plus Regimen</title>
          <description>glargine once daily plus corrective doses of glulisine before meals and bedtime as needed
Basal Plus : glargine once daily plus corrective doses of glulisine before meals and bedtime as needed</description>
        </group>
        <group group_id="P3">
          <title>Sliding Scale Regular Insulin (SSRI)</title>
          <description>four-time daily in patients with T2DM admitted to general medicine and surgery wards.
sliding scale regular insulin (SSRI) : four-time daily in patients with T2DM admitted to general medicine and surgery wards.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="142"/>
                <participants group_id="P3" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="133"/>
                <participants group_id="P3" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>received regimen &lt; 24 hours</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>received steroids</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>transferred to ICU</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Basal Bolus</title>
          <description>glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)
Basal Bolus : glargine once daily plus glulisine before meals subcut at an initial dose of 0.3-0.5 unitws/kg/day (plus corrective doses of glulisine as needed)</description>
        </group>
        <group group_id="B2">
          <title>Basal Plus Regimen</title>
          <description>glargine once daily plus corrective doses of glulisine before meals and bedtime as needed
Basal Plus : glargine once daily subcut at an initial dose of 0.15-0.25 units/kg/day plus corrective doses of glulisine subcut before meals and bedtime as needed</description>
        </group>
        <group group_id="B3">
          <title>Sliding Scale Regular Insulin (SSRI)</title>
          <description>four-time daily in patients with T2DM admitted to general medicine and surgery wards.
sliding scale regular insulin (SSRI) given subcut four-times daily before meals and at bedtime</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="153"/>
            <count group_id="B2" value="142"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="375"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.7" spread="11"/>
                    <measurement group_id="B2" value="58.6" spread="13"/>
                    <measurement group_id="B3" value="58.7" spread="12"/>
                    <measurement group_id="B4" value="58.6" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Determine Glycemic Control Between Basal Plus(Glargine Once Daily Plus Corrective Doses of Glulisine Before Meals and Bedtime as Needed), Basal Bolus Approach of Glargine Once Daily Plus Glulisine Before Meals and SSRI</title>
        <time_frame>during hospitalization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Plus Regimen</title>
            <description>glargine once daily plus corrective doses of glulisine before meals and bedtime as needed
Basal Plus: glargine once daily plus corrective doses of glulisine before meals and bedtime as needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus</title>
            <description>glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)
Basal Bolus: glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)</description>
          </group>
          <group group_id="O3">
            <title>Sliding Scale Regular Insulin (SSRI)</title>
            <description>four-time daily in patients with T2DM admitted to general medicine and surgery wards.
sliding scale regular insulin (SSRI): four-time daily in patients with T2DM admitted to general medicine and surgery wards.</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine Glycemic Control Between Basal Plus(Glargine Once Daily Plus Corrective Doses of Glulisine Before Meals and Bedtime as Needed), Basal Bolus Approach of Glargine Once Daily Plus Glulisine Before Meals and SSRI</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156" spread="36"/>
                    <measurement group_id="O2" value="163" spread="37"/>
                    <measurement group_id="O3" value="172" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine Differences Between Treatments Arms in # of Hypoglycemic Events</title>
        <time_frame>during hospitalization</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During days 1-10 of the study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Basal Plus Regimen</title>
          <description>glargine once daily plus corrective doses of glulisine before meals and bedtime as needed
Basal Plus: glargine once daily plus corrective doses of glulisine before meals and bedtime as needed</description>
        </group>
        <group group_id="E2">
          <title>Basal Bolus</title>
          <description>glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)
Basal Bolus: glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)</description>
        </group>
        <group group_id="E3">
          <title>Sliding Scale Regular Insulin (SSRI)</title>
          <description>four-time daily in patients with T2DM admitted to general medicine and surgery wards.
sliding scale regular insulin (SSRI): four-time daily in patients with T2DM admitted to general medicine and surgery wards.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Severe hypoglycemia</sub_title>
                <description>blood glucose &lt; 40 mg/dl</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>blood glucose &lt; 70 mg/dl</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Guillermo Umpierrez</name_or_title>
      <organization>EUSOM</organization>
      <phone>4047781665</phone>
      <email>geumpie@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

